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T
he need for new pharmaceutical 
tools to prevent and treat 
neglected diseases is widely 
accepted [1]. The creation of a 
vaccine for HIV/AIDS, more effective 
diagnostics for tuberculosis (TB), and 
better treatments for leishmaniasis 
and sleeping sickness would greatly 
improve health in the developing 
world in line with the United Nations 
Millennium Development Goals. 
However, funders wishing to invest in 
this vitally important area currently face 
an information gap. 
There is little consensus on what 
constitutes a neglected disease or 
what new products are required [2]. 
Health research funding figures have 
been published by the Council on 
Health Research for Development 
and the Global Forum for Health 
Research [3,4], but these do not 
disaggregate product-related research 
and development (R&D) or neglected 
disease investments.
Specific R&D investment data 
are available for some neglected 
diseases—including annual surveys of 
HIV/AIDS and TB funding since 2000 
and 2005, respectively [5,6], and a 
one-off survey of malaria R&D funding 
published in 2005 [7]—but these 
cannot readily be compared since each 
survey uses different methodologies 
and covers different diseases, products, 
donors, and countries. For most 
neglected diseases, there is simply no 
information.
In order to address these 
information deficits, the Bill & Melinda 
Gates Foundation commissioned the 
George Institute for International 
Health to conduct five sequential 
annual surveys of global investment 
into R&D of new pharmaceutical 
products to prevent, manage, or cure 
diseases of the developing world. This 
article summarises key data from the 
first G-FINDER report (http://www.
thegeorgeinstitute.org/prpppubs).
Methodology
The chief principle of the G-FINDER 
survey was to provide consistent, 
comparable, comprehensive data on 
neglected disease R&D investments to 
those working in the field. 
Survey design therefore focused on 
two elements. The first was disease, 
product, and research scope; the 
second was design of the survey tool 
that would be used to collect the data. 
Both were determined in consultation 
with an international Advisory 
Committee and Stakeholder Network 
(see Text S1 and S2). 
The Advisory Committee included 17 
international public health and product 
development experts who provided 
advice on inclusion and exclusion of 
diseases and products, and specialist 
knowledge of funders and developers 
in the neglected disease field. The 
Stakeholder Network included 25 major 
funders and product developers who 
advised on survey design, in particular 
on how to best achieve balance between 
the level of detail funders would find 
useful and the level they could feasibly 
provide. This network also provided 
input on issues to be managed in the 
design process, such as national and 
organisational variations in record-
keeping and classification systems; 
multi-year disbursements; allocation 
of platform research and core funding 
between different diseases; overheads; 
double-counting of donor funding 
by intermediary or recipient bodies; 
and variations in financial years and 
currencies. 
Disease, product, and research 
scope. In order to create maximum 
utility for funders, G-FINDER was 
designed to include all neglected 
diseases and products of significance 
to developing countries. This included 
not only Type III diseases, which are 
“overwhelmingly or exclusively incident 
in the developing countries”, but also 
developing-country presentations of 
Type II diseases, which are “incident in 
both rich and poor countries, but with 
a substantial proportion of the cases in 
the poor countries” and where R&D 
is “not in proportion to global need 
or addressed to the specific disease 
conditions of poor countries” [8]. Type 
I diseases, which occur commonly in 
both rich and poor countries, were 
excluded on the grounds that “the 
incentives for R&D exist in the rich 
country markets [and therefore]…
products get developed” [8].
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The first difficulty was to reach 
agreement on what constituted a 
neglected disease, since differing 
lists were used by the World Health 
Organization, the Commission on 
Macroeconomics and Health, the 
Global Network for Tropical Diseases, 
and a range of academic authors 
[8–12]. We therefore created a 
matrix of all Type II and III diseases 
that had been nominated by a major 
health organisation or publication as 
neglected diseases of the developing 
world, and all relevant products for 
each disease. A detailed list of R&D 
activities for each disease and product 
was also prepared based on previous 
categorisations developed by the 
United States National Institutes of 
Health (NIH) and the Wellcome Trust 
[13,14].
These lists were then submitted 
to the Advisory Committee, who 
were asked to include or exclude 
diseases and products based on three 
filtering criteria (Figure 1). They 
were also asked to confirm or amend 
the detailed list of R&D activities for 
each product disease area. This was 
particularly important for diagnostics, 
vector-control products, and platform 
technologies, where development 
pathways for commercial and public 
health markets can differ. 
This consultation process resulted in 
an agreed list of 30 neglected diseases 
and 127 neglected disease-product 
areas for which new product investment 
was needed (see Table 1), and a 
prescriptive list of which R&D activities 
were included and excluded. 
Inclusion of investment data for 
some disease-product areas was 
“restricted”, that is, only developing-
country-specific R&D investments 
could be included as defined in the 
detailed list of R&D activities. This 
was important to prevent neglected 
disease data being swamped by “white 
noise” from overlapping commercial 
R&D investments (e.g., in HIV and 
pneumonia); by investments in 
platform technologies with shared 
Western, as well as potential developing 
country, applications (e.g., adjuvants, 
diagnostic platforms); or by funding 
for activities not directly related to 
product development (e.g., advocacy, 
behavioural research). 
The definition of what constituted 
a “developing-country-specific” 
investment for each restricted disease 
and product category was reached 
through an intensive consultation 
process over four months with the 
Advisory Committee. In some cases, 
views of additional disease experts 
were sought before consensus could 
be reached. This resulted in a tailored 
set of criteria for each restricted 
disease-product category, reflecting 
differences in disease and product 
profiles, research approaches, and 
products already available. The 
example of vaccines for bacterial 
pneumonia and meningitis is given 
below. 
The Advisory Committee consensus 
was that vaccines for only two strains of 
bacterial pneumonia and meningitis 
(Streptococcus pneumoniae and Neisseria
meningitidis) should be eligible for 
inclusion in G-FINDER. Within this, 
the Committee defined “developing-
country-specific” products, for which 
investments could be included, as 
those that met the following criteria. 
For S. pneumoniae, the vaccine should 
be, at a minimum, designed for 
use in infants less than two years of 
age and provide coverage against S.
pneumoniae serotypes 1, 5, and 14. For 
N. meningitidis, the vaccine should 
provide coverage against N. meningitidis
serotype A, be a conjugate rather than 
a polysaccharide vaccine, be designed 
for use in infants less than two years 
of age, and be designed to cost less 
than a dollar per dose. For multi-
valent pneumonia vaccines covering 
Western and developing country 
strains, only developing-country-
specific costs were eligible, defined 
as trials, registration, and phase IV/
pharmacovigilance studies carried out 
in the target developing countries for 
the vaccine. (See Text S3 for reference 
document setting out criteria for 
eligible, ineligible, and restricted R&D 
investment for all disease, product, and 
research categories.)
Investment into HIV/AIDS for two 
categories, drugs and basic research, 
was also restricted to funding targeted 
to developing-country-specific 
presentations. For basic research, 
this was defined as research into 
mechanisms related to preventative 
vaccines and microbicides (e.g., 
immunological responses to potential 
antigens, mechanisms of mucosal 
transmission) but excluding general 
research that could also be applied 
to commercial products. Research 
into HIV drugs also included only 
developing-country-specific applications, 
such as label extensions to paediatric 
patient groups, fixed dose combinations, 
and slow release formulations. These 
restrictions were important to prevent 
developing-country-specific funding 
being swamped by the high level of 
public and private investment into HIV 
R&D targeted at Western needs. 
Survey tool and survey process. As 
noted above, G-FINDER sought to 
Figure 1. Three-Step Filter To Determine Scope of Neglected Diseases Covered by G-FINDER
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provide data that were as consistent and 
comprehensive as possible across the 
range of neglected diseases surveyed, in 
order to enable analysis across diseases, 
funders, or regions and, as the survey is 
repeated, over time. 
In order to achieve this, we followed 
two core principles. Firstly, only raw 
primary data reported by the funders, 
product development partnerships 
(PDPs), and product developers 
themselves were included in the survey. 
If these data were not available, they 
were not supplemented with secondary 
data or estimates. Secondly, in order 
to make the data as comparable and 
consistent as possible, all raw primary 
grant data were collected using the 
same online/offline reporting tool and 
inclusion/exclusion framework for all 
survey recipients. The only exception 
was the NIH, where a proportion of 
grants could not be collected in this 
way due to NIH data management 
system changes (see below on how 
exceptions were handled).
Survey participants were asked to 
enter every neglected disease grant 
they had disbursed or received in 
2007 into a password-protected 
online database, including the grant 
amount, grant identification number, 
a brief description of the grant, and 
the name of the funder or recipient 
of the grant. They were also asked 
to confirm their organisation details 
Table 1. Diseases and Products Included in G-FINDER
Disease Basic
Research
Drugs Vaccines
(Preventive)
Diagnostics Microbicides Vaccines
(Therapeutic)
Vector
Control
Products
HIV/AIDS Restricted Restricted Y Y Y
Malaria Plasmodium falciparum YY YY Y
P. vivax YY YY Y
Other and/or unspecified malaria 
strains
YY YY Y
TB YY YY Y
Bacterial
pneumonia & 
meningitis
S. pneumoniae Restricted Y
N. meningitidis Restricted Y
Both bacteria Y
Diarrhoeal
diseases
Rotavirus Restricted
Enterotoxigenic Escherichia coli  YY
Cholera Y Restricted Y Y
Shigella Y Restricted Y Y
Cryptosporidium Y Restricted Y Y
Enteroaggregative E. coli  YY
Giardia Y
Multiple diseases Y Y Y Y
Kinetoplastids Chagas disease Y Y Y Y Y Y
Leishmaniasis Y Y Y Y Y
Sleeping sickness Y Y Y Y Y
Multiple diseases Y Y Y Y Y Y
Buruli ulcer YY YY
Dengue YY YY Y
Helminths Roundworm (ascariasis) Y Y
Hookworm (ancylostomiasis & 
necatoriasis)
YY Y
Whipworm (trichuriasis)  Y Y
Strongyloidiasis & other intestinal 
roundworms
YY YY
Lymphatic filariasis (elephantiasis)  Y Y Y
Onchocerciasis (river blindness) Y Y Y Y Y
Schistosomiasis (bilharziasis) Y Y Y Y Y
Tapeworm (cysticercosis/taeniasis)  Y Y Y
Multiple diseases Y Y Y Y Y
Leprosy YY Y
Trachoma YY
Rheumatic fever Y
Typhoid and 
paratyphoid
fever
YY Y
Adjuvants and 
immunomodulators
Delivery technologies and 
devices
     Diagnostic platforms
Platform technologies (non-disease specific) Restricted Restricted      Restricted
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such as role in funding (e.g., funder, 
fund manager, product developer), 
financial year, currency used, type of 
organisation (e.g., private sector firm, 
academic institution, PDP, multilateral 
organisation), and country where they 
were located. Each grant was entered 
using a three-step process where the 
survey recipient had to choose (1) a 
specific disease or sub-disease; (2) a 
product type (e.g., drugs, vaccines, 
microbicides); and (3) a research type 
within the product (e.g., discovery 
and preclinical, clinical development) 
according to pre-determined categories 
as described below. (See Text S4 for 
selected screen shots of the survey 
tool.) Where survey recipients could 
not provide data to this level of detail, 
they were asked to provide the finest 
level of granularity they could, ideally 
to at least disease and product level. 
The option of “Unspecified” was 
available in steps 2 and 3. If survey 
recipients were not able to allocate the 
grant to a single disease in step 1, three 
options were available: 
“Core funding of a multi-disease  s
organisation” (e.g., funding to an 
organisation working in multiple 
diseases, where the expenditure per 
disease was not known to the funder); 
“Platform technologies”, further  s
allocated as investment into 
diagnostic platforms; adjuvants, and 
immunomodulators; or delivery 
device platforms; 
“Other R&D” for any grants that still  s
could not be allocated. 
A separate reporting template 
was developed for multinational 
pharmaceutical companies, since 
these do not operate on a grants basis. 
Companies agreed to provide full data 
on their neglected disease investment. 
These data were defined as salary 
costs of full-time equivalent (FTE) 
staff employed on neglected disease 
programmes, including employment 
costs and benefits but excluding 
overheads; and all non-FTE direct 
project costs according to predefined 
lists developed by G-FINDER. These 
lists included typical R&D activities 
such as screening, medicinal chemistry, 
batch manufacture, and bioanalysis 
studies. Companies were asked to 
allocate their investments by disease, 
product and research type, according 
to the same guidelines used for online 
survey recipients. 
We note that all participants 
agreed to provide actual 2007 grant 
disbursements and investments, as 
opposed to commitments made but not 
yet disbursed, or “soft” figures such as 
in-kind contributions, costs of capital, 
or funding estimates. Organisations 
submitted data based on their financial 
year, rather than the calendar year. 
This system was varied in the case of 
the NIH. Due to restructuring of NIH 
information systems, only the Office 
of AIDS Research and the intramural 
arm of the National Institute of Allergy 
and Infectious Diseases were able to 
provide raw grant data. Taken together, 
these represented 68% of NIH 2007 
expenditures on neglected disease 
R&D accounted for in the survey. On 
the advice of the NIH, the remaining 
32% were obtained and filtered from 
public official databases. 
Raw grant data for selected diseases 
were also shared with and between 
other survey groups (Families USA, 
Treatment Action Group, and the HIV 
Vaccines and Microbicides Resource 
Tracking Working Group) to avoid re-
surveying funders when possible. Any 
raw data received from other groups 
were reviewed, cleaned, and reclassified 
according to G-FINDER guidelines 
prior to entry into the database.
Data were entered over a 10-week 
period from July to September 2008, 
with a final total of 5,116 grants or 
investments recorded in the database. 
Data cleaning and analysis. Survey 
closure was followed by a three-
month period of intensive cleaning, 
cross-checking, and organising of the 
complex dataset collected. 
Prior to commencing cross-checking, 
foreign currencies were converted to 
US dollars based on the 2007 average 
annual exchange rate as reported by 
the International Monetary Fund [15]. 
All non-NIH grants over US$0.5 million 
(i.e., any grant over 0.02% of total 
funding) were then verified through 
a three-step process. Each grant was 
first manually reviewed against our 
inclusion criteria to ensure only 
relevant R&D funding was captured. 
Over 3,000 grants were manually 
checked for correct allocation. 
Automated reconciliation reports were 
then used to cross-check self-reported 
funder data grant-by-grant against 
the funding reported as received by 
product developers and intermediary 
groups such as PDPs in order to identify 
inconsistencies. The final step was 
to resolve any discrepancies through 
direct contact with the funder and 
recipient to identify the correct figure. 
When reported amounts differed 
between funder and recipient due 
to practical factors such as differing 
financial years, the funder’s amount 
was retained over that of the recipient. 
We note that these differences will be 
reconciled as the survey is repeated 
over the years. Industry figures were 
reviewed against industry portfolio 
information held by the George 
Institute and against FTE and direct 
costs provided by other companies. 
Costs that fell outside the expected 
range, for example, above average FTE 
costs for clinical staff, were queried and 
corrected with the company. 
Analysis was conducted using 
automated reports constructed to 
show multiple data cuts from our 
cleaned and cross-checked database. 
These included calculating funding 
by disease, product, and research 
areas and possible combinations of 
these; and by funder, geographical 
region, recipient type, and so 
forth, with summary findings set 
out below. Industry figures were 
analysed at aggregate level, rather 
than by individual company. This 
included analysis of multinational 
pharmaceutical company aggregate 
contributions and small company 
aggregate contributions. 
Scope of recipients. In its first year, 
G-FINDER sought to capture 2007 
data from a wide range of funders and 
countries including:
Public, private, and philanthropic  s
funders in high- and middle-income 
countries that were part of the 
Organisation for Economic Co-
operation and Development (OECD); 
all European Union Member States; 
and other high- and middle-income 
countries known to have an active 
research base (Singapore, Israel, and 
the Russian Federation) 
Public funders in selected innovative  s
developing countries—IDCs (South 
Africa, Brazil). 
In subsequent years, the survey 
will expand to include private sector 
funding in these two IDCs, as well as 
public funding in additional IDCs 
(India, China, Cuba) and other low- 
and middle-income countries.PLoS Medicine  |  www.plosmedicine.org 0141 February 2009  |  Volume 6  |  Issue 2  |  e1000030
Potential funders were identified 
through a number of avenues. The 
Health Policy Division has been 
working in the neglected disease 
field since 2004, during which time 
we have developed a large internal 
database of neglected disease 
funders, intermediaries, and product 
developers. This knowledge was built 
through scanning portfolios, media 
releases, industry reports, conference 
presentations, personal contacts, 
and in our role as Expert Advisors 
on a previous funding survey (the 
Malaria R&D Alliance survey of 2005). 
Previous neglected disease surveys 
have also collated lists of funders, 
intermediaries, and developers working 
in HIV, TB, and malaria; and we 
liaised closely with these survey groups, 
and with our Advisory Committee, 
to exchange information on known 
organisations in the field. Collation 
of this information resulted in a list 
of 551 organisations in the 43 target 
countries, who had previously recorded 
involvement in neglected disease 
product development. Of these, 134 
were funders (the target group for the 
survey).
These 500-plus potential survey 
recipients were prioritised based on 
their R&D role (funder, developer, 
intermediary such as PDPs), level 
of funding, and area of disease and 
product activity.
Our top priority, as noted, was to 
target funders; however, it was known 
that some funders played a more 
pivotal role than others. For example, 
previous surveys had identified that 
88% of malaria R&D funding [7] ; 88% 
of HIV R&D funding [5] ; and 83% 
of TB funding [6] were due to only 
12 funders in each area, with these 
funders showing significant overlap 
across the three diseases. Based on 
published levels of funder investment 
in previous surveys, we were able to 
sub-divide the 134 funders into three 
groups. Maximum priority funders 
were defined as groups known to 
have previously invested over US$10 
million dollars in neglected disease 
R&D funding annually; high priority 
funders were defined as groups known 
to have provided over US$5 million 
but less than US$10 million dollars; 
low priority were defined as groups 
providing less than US$5 million per 
year. The 43 participating countries (as 
opposed to individual funders) were 
also classified into three priority levels 
according to their gross expenditure 
on R&D (GERD) as a percentage of 
gross domestic product, as reported by 
the OECD [16]. The GERD ranking 
allowed us to identify countries 
that had not appeared in published 
neglected disease surveys, but whose 
high R&D expenditure might 
include domestic organisations with a 
previously unidentified component of 
neglected disease R&D.
All potential survey recipients were 
then reviewed for their activity in 
diseases outside HIV, TB, and malaria, 
to ensure the survey did not overlook 
groups who might only be active in 
other diseases and would therefore not 
have appeared in previous HIV, TB, 
and malaria funding surveys. Based on 
this review, on our internal database, 
and on advice from our Advisory 
Committee, we identified known or 
suspected major funders, PDPs, and 
product developers (public, academic, 
and private) for the remaining 27 
G-FINDER diseases. If not already 
included, these were added to our high 
priority group.
This prioritisation process resulted 
in three survey strata, as follows. The 
maximum priority group included 
25 organisations known to be major 
funders (over US$10 million per year) 
or major private sector developers 
investing internally in the 30 target 
Figure 2. HIV/AIDS R&D Funding in 2007
doi:10.1371/journal.pmed.1000030.g002
Figure 3. Malaria R&D Funding in 2007
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neglected diseases. The high priority 
group of 85 organisations included 
known significant funders (US$5–
US$10 million per year); potential 
research funders in high-GERD 
countries; and a range of academic 
research institutes, PDPs, government 
research institutes, multilaterals, 
multinational pharmaceutical firms, 
and small companies, who collectively 
provided good coverage of all 
disease areas. The remaining survey 
recipients, classified as low priority, 
were known very small funders 
or other known grant recipients, 
including many academic groups 
and public research institutions. 
We note that, although data from 
grant recipients were not included 
in the survey, they were collected to 
underpin the cross-checking process 
and track funding flows through the 
system. In addition, they provided 
extremely useful insights into how and 
where neglected disease research is 
conducted. 
The G-FINDER process focused on 
the 110 organisations included in the 
maximum and high priority groups, 
who likely represented the majority of 
global neglected disease R&D funding. 
Substantial pro-active effort was put 
into securing high survey completion 
and data accuracy rates from these 
groups. The remaining groups were 
passively surveyed, but not pro-actively 
pursued for information.
We received complete financial 
information from 150 organisations. 
In the maximum priority group, 23 of 
25 recipients (92%) provided funding 
information for 2007. Two maximum 
priority organisations, Wyeth-Ayerst 
Lederle and Merck (both multinational 
pharmaceutical companies), did not 
provide data; and one, sanofi-aventis, 
provided incomplete data (drug but 
not vaccine data). In the high priority 
group, 77 organisations (91%) provided 
full funding information for 2007. 
Survey Findings
Overall funding. Just over US$2.5 
billion was invested into R&D of new 
neglected disease products in 2007. 
Funding was highly concentrated, 
with HIV/AIDS, TB, and malaria 
receiving nearly 80% of the total (see 
Table 2). Other equally high-burden 
diseases as measured by DALYs 
(disability-adjusted life years), such 
as pneumonia and the diarrhoeal 
illnesses, collectively received less than 
6% of total funding. 
Overall, product R&D investment 
was heavily focused on drugs and 
vaccines. Investment in new diagnostics 
was patchy, while platform technologies 
applicable to many diseases, for 
instance vaccine adjuvants, diagnostic 
platforms, and delivery technologies, 
received less than 0.4% of total R&D 
investment.
Funding for “the big three”: HIV/
AIDS, malaria, and TB. Total R&D 
funding for HIV/AIDS was US$1.08 
billion, with US$692 million (63.9%) 
directed to vaccines, US$200 million 
(18.4%) to microbicides, and US$176 
million (16.2%) to basic research. Less 
than US$1 million (0.1%) was invested 
in development of HIV drugs targeted 
at developing world needs, such as 
paediatric formulations and fixed-dose 
antiretroviral combinations (Figure 2). 
Total funding for malaria was 
US$468.5 million, with drug 
development receiving nearly half this 
amount (US$214 million or 45.7%). 
Basic research was the next highest 
funded category at US$113 million 
(24.1%), while vaccines received 
US$88.4 million (18.9%). Vector 
control products, such as insecticides 
and biological control measures, 
received US$17.7 million. Malaria 
diagnostics received very limited 
funding of US$1.6 million (0.3% of the 
total) (Figure 3). 
TB funding for 2007 totalled 
US$410.4 million. As with malaria 
investments, the bulk of this went to 
R&D of TB drugs (US$145.1 million 
or 35.3%), closely followed by basic 
research at US$132.4 million (32.3%). 
TB vaccines were funded at similar 
levels to malaria vaccines in both 
actual and relative terms, receiving 
US$82.3 million (20%) of total TB 
funding. However, TB diagnostics 
fared dramatically better, receiving 
8.5% of global TB investment (US$35 
million) (Figure 4). 
Neglected Disease Funders: Who 
Are They?
Funding by sector. Neglected disease 
funding remains primarily the realm 
of public and philanthropic donors, 
who collectively invested US$2.3 billion 
or 90% of the total funding in 2007 
(Figure 5). 
Public donors, including government 
and multilateral groups, provided 
Table 2. Total R&D Funding by Disease
Disease Amount (US$)  % of Total 
Funding
HIV/AIDS 1,083,018,193 42.30
Malaria 468,449,438 18.30
Tuberculosis 410,428,697 16.03
Kinetoplastids 125,122,839 4.89
Diarrhoeal diseases 113,889,118 4.45
Dengue 82,013,895 3.20
Helminths (worms and flukes) 51,591,838 2.02
Bacterial pneumonia and meningitis 32,517,311 1.27
Typhoid and paratyphoid fever 9,117,212 0.36
Leprosy 5,619,475 0.22
Buruli ulcer 2,412,950 0.09
Trachoma 1,679,711 0.07
Rheumatic fever 1,670,089 0.07
Cannot be allocated to one disease 120,918,862 4.72
Core funding of a multi-disease R&D organisation 110,921,673 4.33
General diagnostic platforms 4,791,152 0.19
Adjuvants and immunomodulators 2,685,148 0.10
Delivery technologies and devices 2,520,889 0.10
Other R&D 51,619,120 2.02
Grand Total 2,560,068,749  100.00
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US$1.78 billion (69%) while 
philanthropic and not-for-profit 
funders invested US$538 million 
(21%). Although only two IDCs 
were included in year one of the 
survey, they represented 1% of global 
spending. IDC figures are expected to 
be substantially larger in subsequent 
G-FINDER surveys due to the inclusion 
of India, China, and Cuba.
The private pharmaceutical industry 
provided around 9% of the global 
total, with an aggregate investment 
of US$231.8 million. This collectively 
made the pharmaceutical industry 
the third largest global investor in 
neglected disease R&D behind the 
NIH and the Bill & Melinda Gates 
Foundation. Small companies and 
biotechs represented around 20% 
of reported industry investment 
(US$46.2 million), with multinational 
firms contributing US$185.7 million 
(80%). 
Funding by government. The US 
Government represented nearly three 
quarters of global public spending 
with an investment of US$1.25 billion 
(70%) through its various institutes 
and departments (Table 3). European 
Governments and the European 
Commission collectively provided 
US$384.9 million (22%), with the UK, 
the Netherlands, Republic of Ireland, 
and Sweden dominating the field. The 
increasing role played by some non-G7 
economies was notable, with Brazil 
ranking as the 6th largest government 
funder and Russia as the 10th. 
Funding by organisation. It was 
also illuminating to examine funding 
from the perspective of individual 
organisations. This showed that global 
investment into creating new neglected 
disease products is heavily reliant on 
a mere handful of donors. Twelve 
organisations provided around 80% 
of global funding, with the NIH and 
the Bill & Melinda Gates Foundation 
collectively investing US$1.51 billion or 
59.5% of the total (Table 4). 
For confidentiality reasons, industry 
investments were aggregated. However, 
we note that if this had not been the 
case, some pharmaceutical companies 
would have appeared in the list of top 
12 funders based on the size of their 
internal investments. 
Funding Recipients: Who Are 
They?
Neglected disease R&D is conducted by 
a wide variety of organisations, including 
academic groups, public institutions, 
and private companies. Some rely 
entirely on external grants for their 
neglected disease R&D programmes, 
while others fund their programmes 
from their own budgets, and yet others 
operate on a mix of both. 
Funders also appeared to 
increasingly rely on PDPs to manage 
and allocate funding (Table 5). Twenty-
three percent of donor funding was 
routed via PDPs, who reallocated it 
to industry and academic partner 
programmes, rather than being 
granted directly by donors to recipient 
organisations.
Discussion
Limitations to the methodology. 
G-FINDER is, we believe, the most 
rigorous neglected disease R&D 
survey conducted to date in terms of 
Figure 4. TB R&D Funding in 2007 
doi:10.1371/journal.pmed.1000030.g004
Figure 5. Total R&D Funding by Funder Type in 2007
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its scope, methodology, and breadth 
of participation. Strenuous efforts 
were made to reach agreement on 
definitions of diseases, products, 
and research activities for inclusion. 
Equal effort was put into designing a 
data collection system that provided 
an identical reporting framework for 
each organisation, despite differences 
in currency, financial year, research 
categorisation, and reporting systems. 
By collecting primary raw grant and 
investment data in the same way 
from all organisations, we believe the 
G-FINDER survey allows for a more 
accurate comparison of funding across 
the range of neglected diseases than 
has been possible before. 
However, it is also important to 
note the limitations of the survey. 
The greatest limitation is survey non-
completion, particularly by maximum 
priority groups who are by definition 
major funders or play a significant 
R&D role in a specific disease-product 
area. We believe that data from public
maximum priority funders are close 
to 100% complete, since all identified 
public groups provided full data. 
However, private sector figures are 
almost certainly under-reported due to 
the non-participation of two maximum 
priority multinational pharmaceutical 
companies and provision of incomplete 
data by another. We note that at least 
one of these companies has a late-stage 
pneumonia vaccine programme for 
commercial markets; however, this 
may have included some investment 
in developing country studies that will 
have been missed. One of the three 
firms also had a late-stage HIV vaccine 
in development, which will have led 
to significant under-reporting of AIDS 
vaccine investments. 
A second area where missing private 
sector data are likely to distort results 
is that of diagnostics, where smaller 
companies play an active role. A total of 
150 small firms were identified as having 
neglected disease R&D activity, many 
of them working in the diagnostic field, 
particularly HIV and TB diagnostics; 
however, only 28 of these provided 
data for the survey. The plethora of 
small firms in the diagnostic field is 
likely to reflect the substantially lower 
development cost and time of bringing 
new diagnostics to market, compared to 
developing new drugs and vaccines. Low 
participation rates by these small firms 
mean diagnostic investments are likely 
to be under-reported, particularly in 
HIV and TB. As a result, the diagnostic 
funding reported in G-FINDER for 
these two diseases needs to be treated 
with caution. 
It is also important to note other 
factors that are likely to have led 
to under-estimation of the value of 
industry investments. Companies who 
participated in the survey agreed to 
exclude costs that were difficult to 
quantify in order to avoid degrading 
the quality of data—for instance, costs 
of capital, infrastructure costs, and 
Table 4. Top 12 Funders by Organisation
Rank Funder Amount (US$) % of Total Funding
 1 US National Institutes of Health  1,064,859,791 41.75%
 2 Bill & Melinda Gates Foundation  452,102,715 17.72%
 3 European Commission   121,366,882  4.76%
 4 US Department of Defense  86,914,578  3.41%
 5
United States Agency for International 
Development
 80,600,336  3.16%
 6 Wellcome Trust  59,985,371  2.35%
 7 UK Medical Research Council   51,716,968  2.03%
 8 Department for International Development   47,565,987  1.86%
 9 Netherlands Ministry of Foreign Affairs   33,951,646  1.33%
 10 Pasteur Institute  31,617,540  1.24%
 11 Irish Aid  24,271,557  0.95%
 12 Swedish International Development Agency   21,529,014  0.84%
Sub Total 2,076,482,385 81.11%
Total R&D Funding 2,560,068,749
doi:10.1371/journal.pmed.1000030.t004
Table 5. Funds Received by PDPs and TDR 
PDPs and TDR Amount (US$)
International AIDS Vaccine Initiative 81,297,482
Medicines for Malaria Venture  75,982,931
European and Developing Countries Clinical Trials Partnership  50,803,467
International Partnership for Microbicides  46,311,916
Aeras Global TB Vaccine Foundation  40,121,983
Global Alliance for TB Drug Development  39,587,358
PATH Malaria Vaccine Initiative/PATH Meningitis Vaccine Project  38,024,679
TDR 32,675,307
Drugs for Neglected Diseases initiative  28,520,251
Institute for One World Health  27,377,321
Other PDPs 123,671,134
Total Funding to PDPs and TDR  584,373,827
TDR, Special Programme for Research and Training in Tropical Diseases. 
doi:10.1371/journal.pmed.1000030.t005
Table 3. Top 12 Government/Public Funders
Rank Country Amount (US$) % of Total 
Funding
1 United States of America 1,250,935,091 70.39%
2 European Commission 121,366,882 6.83%
3 United Kingdom 100,781,214 5.67%
4 The Netherlands 34,088,694 1.92%
5 Ireland 24,271,557 1.37%
6 Brazil 21,970,169 1.24%
7 Sweden 21,566,527 1.21%
8 Canada 19,134,610 1.08%
9 Australia 18,166,780 1.02%
10 Russia 16,666,666 0.94%
11 Belgium 15,851,130 0.89%
12 France 13,892,238 0.78%
Total Public Funding 1,777,173,493
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the value of in-kind contributions. 
Although difficult to quantify, these 
inputs nevertheless have a substantial 
value and represent a substantial 
unrecognised cost to companies. 
Differing level of responsiveness 
between organisations and countries 
may also skew findings. For instance, it 
is possible that the Australian location 
of the G-FINDER group led to high 
levels of responsiveness from Australian 
funders, or that funders in non-English-
speaking settings were less enthusiastic 
in their levels of response. This is not 
known to be the case, but is simply 
noted as a possible factor.
Finally, G-FINDER can only 
report the data that were given to us. 
Although strenuous efforts were made 
to check the classification, accuracy, 
and completeness of grants, in a survey 
this size it is likely that some data will 
still have been incorrectly entered 
or that donors may have accidentally 
omitted some grants. The requirement 
to use public official databases for some 
NIH data, as opposed to raw grant data, 
also means these figures may contain 
inaccuracies or omissions that we were 
unable to detect. We believe, however, 
that the checks and balances built into 
the G-FINDER process mean that such 
mistakes, if present, will have a minor 
impact.
Observations. The G-FINDER 
survey is intended to report accurate, 
comparable R&D investment figures 
across the spectrum of neglected 
diseases. We are not seeking to analyse 
whether investment is best spent, or to 
make recommendations on funding 
allocation; nor are we attempting the 
task of ascertaining how much R&D 
funding is “enough”. Although we 
acknowledge the importance of these 
questions, it would require a research 
effort of equal or greater scope to the 
task undertaken here. The G-FINDER 
report is simply the first step in the 
process, providing information to allow 
discussion and decision-making to begin. 
We therefore restrict ourselves to 
a few observations. The first is that 
research funding is highly concentrated 
and has little correlation with burden 
of disease, as measured by DALYs.
For instance, HIV, TB, and malaria 
accounted for 125 million DALYs in 
low- and middle-income countries in 
2004 [17] and received nearly 80% of 
total funding; while pneumonia and 
the diarrhoeal illnesses accounted for 
165 million DALYs in these countries 
in the same year [17] but received less 
than 6% of total funding. Likewise,
helminth infections received less 
than half the funding of kinetoplastid 
diseases although their disease burden 
was three times higher (12 million 
DALYs in 2004 compared to 4 million 
DALYs for the kinetoplastid diseases) 
[17]; while dengue had a disease 
burden 20 times lower than helminth 
infections at 600,000 DALYs in 2004 
[17] but received nearly twice as much 
funding (see Table 2).
This observation should not be 
construed as a statement or belief that 
funding levels can or should be based 
only on disease DALYs. DALYs are 
the most widely accepted quantitative 
indicator of burden of disease, but 
remain an imperfect measure. For 
some diseases, such as Buruli ulcer, 
reliable DALYs are virtually non-
existent; correct estimates can be 
difficult to obtain in regions with 
weak data; and DALYs do not reflect 
the impact of co-morbidities, such as 
HIV and TB. The DALY comparison 
is noted here chiefly to give a sense of 
the differences in scale of funding for 
different diseases. 
It is important to note, however, 
that funding levels reflect many factors 
beyond DALYs. The current state of 
science for a given disease plays a 
role, since many would-be investors in 
product development look at feasibility 
as well as need. Conversely, other 
investors may specifically choose to 
invest in areas where science is lacking, 
believing their best contribution will be 
funding a breakthrough discovery to 
unlock the path to new products.
Funders may also look at the state 
of existing therapies, preferring to 
focus on areas where no safe effective 
treatments exist (for example, some 
kinetoplastid diseases) to areas where 
treatments exist even though they may 
be limited or sub-optimal (for example, 
some helminth infections). Funders 
may also want to focus on diseases with 
a higher relative or absolute mortality, 
such as dengue or meningitis, rather 
than diseases with lower relative 
mortality but a higher DALY burden. 
The type of R&D needed in a given 
disease area is also a crucial factor 
in interpreting the data, since R&D 
costs vary dramatically depending on 
the kind of product being developed 
and how far down the development 
pathway that product is. Vaccines are 
far more expensive to develop than 
drugs, and drugs than diagnostics. 
Clinical development is also far more 
expensive than pre-clinical or discovery 
research. For instance, out-of-pocket 
development cost of a diagnostic test 
can be in the low tens of millions; 
while clinical development cost of a 
novel fixed-dose combination anti-
malarial is estimated at US$30 million, 
and of a malaria vaccine at just over 
US$100 million [18]. Thus, far more 
investment would be needed to 
develop a meningitis vaccine than a 
TB diagnostic, irrespective of the lower 
burden of disease for meningitis or 
a more advanced state of meningitis 
vaccine technology. 
Despite this, the concentration of 
funding on AIDS, TB, and malaria 
nevertheless suggests that investment 
decisions are not only influenced 
by scientific or epidemiological 
considerations, but may also be 
influenced by factors such as the 
presence of PDPs or civil society groups 
with active advocacy, fundraising, 
and investment activities; by funder 
perceptions or preferences; or by the 
presence of policy frameworks and 
funding mechanisms that prioritise 
specific diseases. 
The predominance of research into 
new products for HIV/AIDS, malaria, 
and TB is understandable—and the 
generosity of funding in these areas is a 
credit to donors—however, other high-
burden, high-mortality diseases remain 
badly under-funded: pneumonia and 
the diarrhoeal illnesses stand out in this 
regard. The tendency to focus on drugs 
and vaccines over diagnostics, platform 
technologies, and developing-country-
specific products is also of concern, 
particularly as these latter categories 
can represent a highly effective use 
of resources since any advance will be 
applicable to many neglected diseases 
and products. 
A second observation relates to 
the concentration of funding. The 
participation of so many organisations 
and countries in development of 
new neglected disease products is 
a remarkable and welcome change 
from past decades of inertia and 
neglect. It is clear, however, that these 
efforts are not evenly distributed, with 
several major OECD governments 
missing in action from the top 10, 
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of R&D for neglected diseases. It is 
also remarkable that investment by 
some private firms is now rivalling 
or exceeding spending by many 
public organisations, and indeed 
many G7 and OECD countries. While 
we commend these companies and 
philanthropists, their efforts are 
meant to support, not replace, those 
of wealthy governments around the 
world.
A broadening of funding efforts 
so that all who are able to contribute 
do so, and all diseases receive the 
attention they deserve, would lead to a 
dramatic positive impact on the health 
of developing country patients afflicted 
with these diseases. We very much hope 
that the information presented in the 
G-FINDER report will contribute to this 
process.  
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